State Street Corp Has $42.14 Million Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

State Street Corp grew its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 10.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 5,625,533 shares of the company’s stock after buying an additional 530,645 shares during the period. State Street Corp owned 4.08% of Vir Biotechnology worth $42,135,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of VIR. Innealta Capital LLC acquired a new position in shares of Vir Biotechnology in the 2nd quarter valued at approximately $32,000. Blue Trust Inc. lifted its stake in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Vir Biotechnology in the third quarter valued at approximately $56,000. Magnetar Financial LLC acquired a new position in shares of Vir Biotechnology in the second quarter valued at approximately $95,000. Finally, Quest Partners LLC lifted its position in Vir Biotechnology by 142.1% in the 2nd quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after acquiring an additional 7,452 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on VIR. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Finally, Barclays cut their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $36.40.

Vir Biotechnology Trading Down 0.4 %

Vir Biotechnology stock opened at $7.34 on Friday. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -1.87 and a beta of 0.49. The firm’s fifty day moving average price is $8.02 and its two-hundred day moving average price is $8.55. Vir Biotechnology, Inc. has a 1-year low of $6.56 and a 1-year high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The business had revenue of $2.38 million during the quarter, compared to the consensus estimate of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Vir Biotechnology’s revenue was down 9.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.22) EPS. On average, research analysts forecast that Vir Biotechnology, Inc. will post -3.36 EPS for the current year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).